Medivir licensee Tango Therapeutics discontinues TNG348 clinical program

Medivir (MVIR) licensee Tango Therapeutics (TNGX) has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts. TNG348 is a novel USP1 inhibitor for the treatment of BRCA1/2-mutant and other homologous recombination deficiency cancers, and has been developed by Tango from the preclinical USP1 program licensed from Medivir in 2020. The announcement by Tango Therapeutics has no impact on Medivir’s focus and development efforts with its lead program fostroxacitabine bralpamide for primary liver cancer.